A study found that litifilimab, a humanized monoclonal antibody that binds blood dendritic cell antigen 2, may be effective for the treatment of patients with active cutaneous lupus erythematosus. The treatment successfully reduced skin disease activity in patients at 16 weeks compared with placebo.
